You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds

    SBC: Initos Pharmaceuticals LLC            Topic: NCATS

    ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies

    SBC: Alterna Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. The Antibody Registry: A Community Authority for Antibody Research Resource Identifiers

    SBC: SCICRUNCH            Topic: 300

    Project SummaryOne of the most glaring yet easily addressable gaps in our current scientific workflow and publication system is improving the way that methods are reportedin particularthe lack of key methodological details necessary for interpreting and reproducing a studyMost authors continue to cite the name of the reagentlike an antibody using the vendorand the city where the vendor is locatedb ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. BlueBox: A Complete Code Blue Data Recorder, Phase II

    SBC: NeoVative, Inc.            Topic: 400

    “Code blue” is the signal used in hospitals to call for an immediate cardiopulmonary resuscitation (CPR) following a cardiac or respiratory arrest. Reviewing the performance of the “code blue team” is a cornerstone for improving outcomes. The current standard of using handwritten records on a paper “code sheet” does not allow measurement of key quality indicators and is subject to huma ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. AHTP-comet: development of an automated, high throughput comet assay system

    SBC: Engineering Resources Group, Inc            Topic: NIEHS

    PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Automated CRISPR Screening Using the CellRaft Technology

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government